scholarly journals Harmine suppresses the proliferation of pancreatic cancer cells and sensitizes pancreatic cancer to gemcitabine treatment

2019 ◽  
Vol Volume 12 ◽  
pp. 4585-4593 ◽  
Author(s):  
Lin-wen Wu ◽  
Jian-kang Zhang ◽  
Mingjun Rao ◽  
Zuo-yan Zhang ◽  
Hua-jian Zhu ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Cancer Cells ◽  
Pancreatic Cancer Cells ◽  
Gemcitabine Treatment

Enhancing responsiveness of pancreatic cancer cells to gemcitabine treatment under hypoxia by heme oxygenase-1 inhibition

2019 ◽  
Vol 207 ◽  
pp. 56-69 ◽  
Author(s):  
Maher Y. Abdalla ◽  
Iman M. Ahmad ◽  
Satyanarayana Rachagani ◽  
Kasturi Banerjee ◽  
Christopher M. Thompson ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Cancer Cells ◽  
Heme Oxygenase ◽  
Heme Oxygenase 1 ◽  
Pancreatic Cancer Cells ◽  
Gemcitabine Treatment

W1761 Genetic Expression Profile Suggesting Synergy Between Omega-3 Fatty Acids and Gemcitabine Treatment On Pancreatic Cancer Cells

2009 ◽  
Vol 136 (5) ◽  
pp. A-936
Author(s):  
Anthony Razzak ◽  
Justin Hering ◽  
Abdul Saied ◽  
Anthony Bais ◽  
Ponnandai Somasundar ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Fatty Acids ◽  
Cancer Cells ◽  
Expression Profile ◽  
Omega 3 Fatty Acids ◽  
Omega 3 ◽  
Genetic Expression ◽  
Pancreatic Cancer Cells ◽  
Gemcitabine Treatment

Abstract 4673: A novel way to sensitize pancreatic cancer cells for gemcitabine treatment

2016 ◽  
Author(s):  
Jingwu Xie ◽  
Dongsheng Gu ◽  
Xiaoli Zhang ◽  
Yanfei Jia ◽  
Gabi Chiorean
Keyword(s):  
Pancreatic Cancer ◽  
Cancer Cells ◽  
Pancreatic Cancer Cells ◽  
Gemcitabine Treatment

scholarly journals Pentoxifylline and pirfenidone sensitize pancreatic cancer cells to gemcitabine treatment

2020 ◽  
Author(s):  
M. Helena Vasconcelos ◽  
Cristina Xavier ◽  
Inês Castro ◽  
Hugo Caires ◽  
Dylan Ferreira ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Cancer Cells ◽  
Pancreatic Cancer Cells ◽  
Gemcitabine Treatment

scholarly journals Soluble VCAM-1 promotes gemcitabine resistance via macrophage infiltration and predicts therapeutic response in pancreatic cancer

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Ryota Takahashi ◽  
Hideaki Ijichi ◽  
Makoto Sano ◽  
Koji Miyabayashi ◽  
Dai Mohri ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Mouse Model ◽  
Cancer Cells ◽  
Advanced Pancreatic Cancer ◽  
Genetically Engineered ◽  
Human Pancreatic Cancer ◽  
Pancreatic Cancer Cells ◽  
Genetically Engineered Mouse Model ◽  
Gemcitabine Treatment

AbstractPancreatic cancer is one of the malignant diseases with the worst prognosis. Resistance to chemotherapy is a major difficulty in treating the disease. We analyzed plasma samples from a genetically engineered mouse model of pancreatic cancer and found soluble vascular cell adhesion molecule-1 (sVCAM-1) increases in response to gemcitabine treatment. VCAM-1 was expressed and secreted by murine and human pancreatic cancer cells. Subcutaneous allograft tumors with overexpression or knock-down of VCAM-1, as well as VCAM-1-blocking treatment in the spontaneous mouse model of pancreatic cancer, revealed that sVCAM-1 promotes tumor growth and resistance to gemcitabine treatment in vivo but not in vitro. By analyzing allograft tumors and co-culture experiments, we found macrophages were attracted by sVCAM-1 to the tumor microenvironment and facilitated resistance to gemcitabine in tumor cells. In a clinical setting, we found that the change of sVCAM-1 in the plasma of patients with advanced pancreatic cancer was an independent prognostic factor for gemcitabine treatment. Collectively, gemcitabine treatment increases the release of sVCAM-1 from pancreatic cancer cells, which attracts macrophages into the tumor, thereby promoting the resistance to gemcitabine treatment. sVCAM-1 may be a potent clinical biomarker and a potential target for the therapy in pancreatic cancer.

Sign in / Sign up

Export Citation Format

Share Document